Autoantibodies in systemic connective tissue disease and ANCA-associated vasculitis, their relationship to interstitial lung diseases and prognosis

1. Doubková M, Skřičková J. Intersticiální plicní postižení a systémová onemocnění pojiva. Stud Pneumol Phtiseol 2013; 73(2): 76–83.

2. Antoniou KM, Margaritopoulos GA, Tomassetti S et al. Interstitial lung disease. Eur Respir Rev 2014; 23(131): 40–54. Dostupné z DOI: <http://dx.doi.org/10.1183/09059180.00009113>.

3. Antoniou KM, Margaritopoulos G, Economidou F et al. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J 2009; 33(4): 882–896. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00152607>.

4. [American Thoracic Society; European Respiratory Society]. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165(2): 277–304. Erratum in Am J Respir Crit Care Med 2002; 166(3): 426.

5. Vencovský J. Jak pomáhá vyšetřování autoprotilátek v diagnostice a hodnocení autoimunitních revmatických chorob? Vnitř Lék 2006; 52(7–8): 697–701.

6. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J 2008; 31(1): 11–20. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00060107>.

7. Self SE. Autoantibody testing for autoimmune disease. Clin Chest Med 2010; 31(3): 415–422. Dostupné z DOI: <http://dx.doi.org/10.1016/j.ccm.2010.04.001>.

8. Bradley B, Branley HM, Egan JJ et al. [British Thoracic Society Interstitial Lung Disease Guideline Group, British Thoracic Society Standards of Care Committee; Thoracic Society of Australia; New Zealand Thoracic Society; Irish Thoracic Society]. Interstitial lung disease guideline: the British thoracic in collaboration with the thoracic society of Australia and New Zealand and the Irish thoracic society. Thorax 2008; 63(Suppl 5): v1-v58. Dostupné z DOI: <http://dx.doi.org/10.1136/thx.2008.101691>. Erratum in Thorax 2008; 63(11): 1029.

9. Vašáková M, Polák J, Matěj R. Postižení plic u systémových onemocnění. In: Vašáková M, Polák J, Matěj R. Intersticiální plicní procesy. Od etiopatogeneze přes radiologický obraz k histopatologické diagnóze. Maxdorf: Praha 2011: 285–312. ISBN 978–80–7345–251–3.

10. Lamblin C, Bergoin C, Saelens T et al. Interstitial lung diseases in collagen vascular disease. Eur Respir J Suppl 2001; 32: 69s-80s.

11. Bonela F, Costabel U. Biomarkers in connective tissue disease-associated interstitial lung disease. Semin Respir Crit Care Med 2014; 35(2): 181–200. Dostupné z DOI: <http://dx.doi.org/10.1055/s-0034–1371527>.

12. Papiris SA, Kagouridis K, Bouros D. Serologic evaluation in idiopathic interstitial pneumonias. Curr Opin Med 2012; 18(5): 433–440. Dostupné z DOI: <http://dx.doi.org/10.1097/MCP.0b013e3283560840>.

13. Groen H, ter Borg EJ, Postma DS et al. Pulmonary function in systemic lupus erythematosus is related to distinct clinical, serologic, and nailfold capillary patterns. Am J Med 1992; 93(6): 619–627.

14. Boulware DW, Hedgpeth MT. Lupus pneumonitis and anti-SSA(Ro) antibodies. J Rheumatol 1989; 16(4): 479–481.

15. Aubart F, Crestani B, Nicaise-Roland P et al. High levels of anti-cyclic citrullinated peptide autoantibodies are associated with co-occurrence of pulmonary diseases with rheumatoid arthritis. J Rheumatol 2011; 38(6): 979–982. Dostupné z DOI: <http://dx.doi.org/10.3899/jrheum.101261>.

16. Yazisiz V, Arslan G, Ozbudak IH et al. Lung involvement in patients with primary Sjögren’s syndrome: what are the predictors? Rheumatol Int 2010; 30(10): 1317–1324. Dostupné z DOI: <http://dx.doi.org/10.1007/s00296–009–1152–8>.

17. Davidson BK, Kelly CA, Griffiths ID. Ten year follow up of pulmonary function in patients with primary Sjögren‘s syndrome. Ann Rheum Dis 2000; 59(9): 709–712.

18. Fertig N, Domsic RT, Rodriguez-Reyna T et al. Anti-U11/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis. Arthritis Rheum 2009; 61(7): 958–965. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24586>.

19. Hill MB, Phipps JL, Cartwright RJ et al. Antibodies to membranes of endothelial cells and fibroblasts in scleroderma. Clin Exp Immunol 1996; 106(3): 491–497.

20. Mimori T, Imura Y, Nakashima R et al. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and patophysiological significance. Curr Opin Rheumatol 2007; 19(6): 523–529.

21. Love LA, Leff RL, Fraser DD et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70(6): 360–374.

22. Mimori T, Nakashima R, Shida N et al. Interstitial lung diseases in myositis: clinical subsets, biomarkers, and treatment. Curr Rheumatol Rep 2012; 14(3): 264–274. Dostupné z DOI: <http://dx.doi.org/10.1007/s11926–012–0246–6>.

23. Hamaguchi Y, Fujimoto M, Mathushita T et al. Common and distinct of clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLos One 2013; 8(4): e60442. Dostupné z DOI: <http://dx.doi.org/10.1371/journal.pone.0060442>.

24. Teruya A, Kawamura K, Ichikado K et al. Successful polymyxin B hemoperfusion treatment associated with serial reduction of serum anti-CADM-140/MDA5 antibody levels in rapidly progressive interstitial lung disease with amyopathic dermatomyositis. Chest 2013; 144(6): 1934–1936. Dostupné z DOI: <http://dx.doi.org/10.1378/chest.13–0186>.

25. Cavagna L, Nuño L, Scirè CA et al. [AENEAS (American, European NEtwork of Antisynthetase Syndrome) collaborative group]. Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: Results From an International Retrospective Multicenter Study. Medicine (Baltimore) 2015; 94(32): e1144. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001144>.

26. Hoshino K, Muro Y, Sugiura K et al. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology 2010; 49(9): 1726–1733. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/keq153>.

27. Bodolay E, Szekanecz Z, Dévényi K et al. Evaluation of interstitial lung diseasse in mixed connective tissue disease (MCTD). Rheumatology 2005; 44(5): 656–661.

28. Homma Y, Ohtsuka Y, Tanimura K et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration 1995; 62(5): 248–251.

29. Corte TJ, Copley SJ, Desai SR et al. Significance of connective tissue disease features in idiopathic interstitial pneumonia. Eur Respir J 2012; 39(3): 661–668. Dostupné z DOI: <http://dx.doi.org/10.1183/09031936.00174910>.

30. Cottin V. Idiopathic interstitial pneumonias with connective tissue diseases features: A review. Respirology 2016; 21: 245–258.

31. Fischer A, Antoniou KM, Brown KK et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J 2015; 46(4): 976–987. Dostupné z DOI: <http://dx.doi.org/10.1183/13993003.00150–2015> a <http://www.ers-education.org/guidelines.aspx>. [19. 5. 2016].

32. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37(2): 187–192.

33. Jennette JC, Falk RJ, Bacon PA et al. 2012 Revised international Chapel Hill Consensus Conference Nomenclature of Vasculitides. Artrhitis Rheum 2013; 65(1): 1–11. Dostupné z DOI: <http://dx.doi.org/10.1002/art.37715>.

34. Davies DJ, Moran JE, Niall JF et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285(6342): 606.

35. Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’ granulomatosis. Lancet 1985; 1(8426): 425–429.

36. Basu N, Watts R, Bajema I et al. EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 2010; 69(10): 1744–1750. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2009.119032>.

37. Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol 1996; 103(2): 253–258.

38. Kallenberg CG. Pathogenesis and treatment of ANCA-associated vasculitides. Clin Exp Rheumatol 2015; 33(4 Suppl 92): S11-S14.

39. Pendergraft WF, Preston GA, Shah RR et al. Autoimmunity is triggered by cPR-3(105–201), a protein complementary to human autoantigen proteinase-3. Nat Med 2004; 10(1): 72–79.

40. Harper L, Cockwell P, Adu D et al. Neutrophil priming and apoptosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Kidney Int 2001; 59(5): 1729–1738.

41. Radford DJ, Savage CO, Nash GB. Treatment of rolling neutrophils with antineutrophil cytoplasmic antibodies causes conversion to firm integrin-mediated adhesion. Arthritis Rheum 2000; 43(6): 1337–1345.

42. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med 2012; 367(3): 214–223. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1108735>.

43. Savige J, Davies D, Falk RJ et al. Antineutrophil cytoplasmic antibodies and associated diseases: a review of the clinical and laboratory features. Kidney Int 2000; 57(3): 846–862.

44. Savige JA, Paspaliaris B, Silvestrini R et al. Immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies. J Clin Pathol 1998; 51(8): 568–575.

45. Savige J, Gillis D, Benson E et al. International consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111(4): 507–513.

46. Radice A, Sinico RA. Antineutrophil cytoplasmic antibodies (ANCA). Autoimmunity 2005; 38(1): 93–103.

47. Radice A, Bianchi L, Sinico RA. Anti-neutrophil cytoplasmic autoantibodies: methodological aspects and clinical signifikance in systemic vasculitis. Autoimmunity Rev 2013; 12(4): 487–495. Dostupné z DOI: <http://dx.doi.org/10.1016/j.autrev.2012.08.008>.

48. Savige J, Dimech W, Fritzler M et al. [International group for Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)]. Addendum to the International Consensus Statement on testing and reporting of neutrophil cytoplasmatic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Path 2003; 120(3): 312–318.

49. Shulte-Pelkum J, Radice A, Norman GL et al. Novel clinical and diagnostic aspects of antineutrophil cytoplasmatic antibodies. J Immunol Res 2014; 2014: 185416. Dostupné z DOI: <http://dx.doi.org/10.1155/2014/185416>.

50. Csernok E, Moosing F. Current and emerging techniques for ANCA detection in vasculitis. Nat Rev Rheumatol 2014; 10(8): 494–501. Dostupné z DOI: <http://dx.doi.org/10.1038/nrrheum.2014.78>.

51. Sinico RA, Di Toma L, Maggiore U et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52(9): 2926–2935.

52. Katsumata Y, Kawaguchi Y, Yamanaka H. Interstitial lung disease with ANCA-associated vasculitis. Clin Med Insights Circ Respir Pulm Med 2015; 9(Suppl 1): 51–56. Dostupné z DOI: <http://dx.doi.org/10.4137/CCRPM.S23314>.

53. Kagiyama N, Takayanagi N, Kanauchi T et al. Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis. BMJ Open Respir Res 2015; 2(1): e000058. Dostupné z DOI: <http://dx.doi.org/10.1136/bmjresp-2014–000058>.

54. Arulkumaran N, Periselneris N, Gaskin G et al. Interstitial lung disease and ANCA-associated vasculitis: a retrospective observational cohort study. Rheumatology 2011; 50(11): 2035–2043. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ker236>.

55. Wiesner O, Russell KA, Lee AS et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not auto-immune vasculitis. Arthritis Rheum 2004; 50(9): 2954–2965.

56. Lally L, Spiera R. Current landscape of antineutrophil cytoplasmic antibody-associated vasculitis. Rheum Dis Clin N Am 2015; 41(1): 1–19, vii. Dostupné z DOI: <http://dx.doi.org/10.1016/j.rdc.2014.09.003>.

57. Kain R, Tadema H, McKinney EF et al. High prevalence of autoantibodies to hLAMP2 in anti-neutrophil cytoplasmic antibody-associated vasculitis. J Am Soc Nephrol 2012; 23(3): 556–566. Dostupné z DOI: <http://dx.doi.org/.1681/ASN.2011030273>.

58. Finkielman JD, Merkel PA, Schroeder D et al. [WGET Research Group]. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147(9): 611–619.

59. Birck R, Schmitt WH, Kaelsch IA et al. Serial ANCA determinations for monitoring disease aktivity in patients with ANCA-Associated vasculitis: systematic review. Am J Kidney Dis 2006; 47(1): 15–23.

60. Kerr GS, Fleisher TA, Hallahan CW et al. Limited prognostic value of changes in antineutrophil cytoplasmic antibody titer in patients with Wegener’s granulomatosis. Arthritis Rheum 1993; 36(3): 365–371.

61. Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis. Rheumatology (Oxford) 2012; 51(1): 100–109. Dostupné z DOI: <http://dx.doi.org/10.1093/rheumatology/ker280>.

62. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener’s granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43(9): 2025–2033.

63. Verstockt B, Bossuyt X, Vanderschueren S et al. There is no benefit in routinely monitoring ANCA titres in patiens with granulomatosis with polyangiitis. Clin Exp Rheumatol 2015; 33(2 Suppl 89): S72-S76.

64. Lionaki S, Blyth ER, Hogan SL et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides. The role of ANCA specifity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum 2012; 64(10): 3452–3462. 10.1002/art.34562

65. Walsh M, Flossmann O, Berden A et al. [European Vasculitis Study Group]. Risk factors for relapse of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012; 64(2):542–548.

66. Mahr A, Katsahian S, Varet H et al. [French Vasculitis Study Group (FVSG) and the European Vasculitis Society (EUVAS)]. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody associated vasculitis – a cluster analysis. Ann Rheum Dis 2013; 72(6): 1003–1010. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012–201750>.